Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q2 2025 ▲▼ | Q3 2025 ▲▼ | Change ▲▼ | Q2 2025 ▲▼ | Q3 2025 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| ABIVAX Société AnonymeADS(ABVX) | 1,267,000 | 1,325,000 | +58,000 | $9.69M | $112.49M | 17.56% | +$102.80M |
| Dianthus Therapeutics, Inc.(DNTH) | 2,341,667 | 2,416,667 | +75,000 | $43.63M | $95.10M | 14.84% | +$51.47M |
| Gossamer Bio, Inc.(GOSS) | 18,350,000 | 17,050,000 | -1,300,000 | $22.57M | $44.84M | 7.00% | +$22.27M |
| Cogent Biosciences, Inc.(COGT) | 2,763,000 | 2,874,111 | +111,111 | $19.84M | $41.27M | 6.44% | +$21.43M |
| ArriVent BioPharma, Inc.(AVBP) | 1,946,054 | 1,971,054 | +25,000 | $42.37M | $36.37M | 5.68% | -$6.00M |
| Ocular Therapeutix, Inc.(OCUL) | 2,425,000 | 2,624,000 | +199,000 | $22.50M | $30.67M | 4.79% | +$8.17M |
| Taysha Gene Therapies, Inc.(TSHA) | 12,592,500 | 9,067,500 | -3,525,000 | $29.09M | $29.65M | 4.63% | +$562.0K |
| Merus N V | 389,000 | 308,000 | -81,000 | $20.46M | $29.00M | 4.53% | +$8.54M |
| Trevi Therapeutics, Inc.(TRVI) | 3,672,000 | 2,815,000 | -857,000 | $20.09M | $25.76M | 4.02% | +$5.67M |
| Mind Medicine Mindmed Inc | 2,130,000 | 2,130,000 | 0 | $13.82M | $25.11M | 3.92% | +$11.29M |
| Apellis Pharmaceuticals Inc COM | 903,500 | 903,500 | 0 | $15.64M | $20.45M | 3.19% | +$4.81M |
| Kymera Therapeutics, Inc.(KYMR) | 266,000 | 360,000 | +94,000 | $11.61M | $20.38M | 3.18% | +$8.77M |
| Centessa Pharmaceuticals PlcADS | 1,030,000 | 830,000 | -200,000 | $13.53M | $20.13M | 3.14% | +$6.59M |
| Pharvaris N V COM | 672,595 | 722,595 | +50,000 | $11.84M | $18.03M | 2.81% | +$6.19M |
| Kalvista Pharmaceuticals Inc | 1,273,333 | 1,273,333 | 0 | $14.40M | $15.51M | 2.42% | +$1.11M |
| Corbus Pharmaceuticals Holdings, Inc.(CRBP) | 1,115,000 | 1,115,000 | 0 | $7.69M | $14.10M | 2.20% | +$6.41M |
| BridgeBio Oncology Therapeutics, Inc.(BBOT) | 0 | 1,043,110 | +1,043,110 | $0 | $12.08M | 1.89% | +$12.08M |
| DBV Technologies S.A.ADS(DBVT) | 1,018,021 | 1,018,021 | 0 | $9.31M | $10.18M | 1.59% | +$865.3K |
| Nuvation Bio Inc.CL A(NUVB) | 7,691,334 | 2,633,334 | -5,058,000 | $15.00M | $9.74M | 1.52% | -$5.25M |
| Cidara Therapeutics Inc | 0 | 100,000 | +100,000 | $0 | $9.58M | 1.49% | +$9.58M |
| Maze Therapeutics, Inc.(MAZE) | 177,667 | 177,667 | 0 | $2.18M | $4.61M | 0.72% | +$2.43M |
| Neurogene Inc.(NGNE) | 303,000 | 252,000 | -51,000 | $4.53M | $4.37M | 0.68% | -$162.7K |
| Unicycive Therapeutics, Inc.(UNCY) | 1,000,000 | 1,000,000 | 0 | $4.77M | $4.36M | 0.68% | -$410.0K |
| PepGen Inc.(PEPG) | 0 | 700,000 | +700,000 | $0 | $3.23M | 0.50% | +$3.23M |
| Structure Therapeutics IncADS | 0 | 115,000 | +115,000 | $0 | $3.22M | 0.50% | +$3.22M |
| Nuvation Bio Inc.W EXP 02 10 202(NUVB) | 154,112 | 104,112 | -50,000 | $300.5K | $385.2K | 0.06% | +$84.7K |
| ARS Pharmaceuticals, Inc.(SPRY) | 1,350,000 | 0 | -1,350,000 | $23.56M | $0 | — | -$23.56M |
| Atyr Pharma Inc | 3,820,000 | 0 | -3,820,000 | $19.37M | $0 | — | -$19.37M |
| Erasca, Inc.(ERAS) | 700,000 | 0 | -700,000 | $889.0K | $0 | — | -$889.0K |
| Helix Acquisition Corp IiCL A | 250,000 | 0 | -250,000 | $2.66M | $0 | — | -$2.66M |
| Kalaris Therapeutics, Inc.(KLRS) | 360,000 | 0 | -360,000 | $961.2K | $0 | — | -$961.2K |
| MoonLake ImmunotherapeuticsCL A(MLTX) | 148,000 | 0 | -148,000 | $6.99M | $0 | — | -$6.99M |
| Tourmaline Bio Inc | 905,000 | 0 | -905,000 | $14.47M | $0 | — | -$14.47M |
| Verona Pharma PlcADS | 337,000 | 0 | -337,000 | $31.87M | $0 | — | -$31.87M |